DOCSLIB.ORG

Protein Microarrays for Validation of Affinity Binders

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Protein Microarrays for Validation of Affinity Binders Protein microarrays for validation of affinity binders MÅRTEN SUNDBERG KTH - Royal Institute of Technology School of Biotechnology Stockholm © Mårten Sundberg Stockholm, December 2011 KTH - Royal Institute of Technology School of Biotechnology Science for Life Laboratory SE-171 21 Solna Sweden Printed By: AJ E-print AB Oxtorgsgatan 9 111 57 Stockholm Sweden ISBN 978-91-7501-149-3 TRITA-BIO Report 2011:23 ISSN 1654-2312 Mårten Sundberg (2011): Protein microarrays for validation of affinity binders, School of Biotechnology, Royal Institute of Technology (KTH), Stockholm, Sweden. ISBN 978-91-7501-149-3 Abstract Is specificity an important issue regarding affinity reagents? What about the validation of affinity reagents today, is it good enough? This depends on the application and the producer of the reagent. Validation should be the most important marketing argument that can be found. Today there is a continuous growth of both the number of affinity reagents that are produced and the different types of affinity reagents that are developed. In proteomics they become more and more important in exploring the human proteome. Therefore, validated affinity reagents should be on top of every proteomic researcher’s list. How should this be accomplished? Better international agreements on how affinity reagents should be tested to be regarded as functional reagents are needed. One of the most important issues is the specificity of the affinity reagent. An international standard for which specific validation that is needed for different kinds of applications would be very useful. In this thesis, it is shown that the protein microarray platform that was established within the HPA project at KTH is a very good tool to determine the specificity of different affinity binders. In the first study, the production of mono-specific antibodies for tissue profiling in the Human Protein Atlas (HPA) project is presented. The section describing the use of protein microarrays for validation of the antibodies is relevant for this thesis. The implementation of protein microarrays in the HPA workflow was an important addition, because a deeper insight of the specificity of all the antibodies produced were now available. In a second study, bead based arrays were compared to planar protein microarrays used in the HPA project. In this study, 100 different bead identities were coupled with 100 different antigens and mixed together to generate an array. The correlation between the two types of assays was very high and the conclusion was that the methods can be used as backup to each other. A third study was a part of an international initiative to produce renewable affinity binders against proteins containing SH2 domain. Here, the HPA protein microarrays were modified to analyze different types of reagents produced at six laboratories around the world. Monoclonal antibodies, single chain fragment and fibronectin scaffolds were tested as well as mono-specific antibodies. It was shown to be possible to adapt protein microarrays used in the HPA project to validate other kinds of affinity reagents. Keywords: Microarray, protein, antibody, antigen, affinity, validation © Mårten Sundberg List of publications This thesis is based upon the following three papers. The papers are included in the Appendix. I. Nilsson, P., Paavilainen, L., Larsson, K., Odling, J., Sundberg, M., Andersson, A. C., Kampf, C., Persson, A., Al-Khalili Szigyarto, C., Ottosson, J., Bjorling, E., Hober, S., Wernerus, H., Wester, K., Ponten, F., and Uhlen, M. (2005) Towards a human proteome atlas: high-throughput generation of mono-specific antibodies for tissue profiling, Proteomics 5, 4327-4337. II. Schwenk, J. M., Lindberg, J., Sundberg, M., Uhlen, M., and Nilsson, P. (2007) Determination of binding specificities in highly multiplexed bead-based assays for antibody proteomics, Mol Cell Proteomics 6, 125-13. III. Sjoberg, R*., Sundberg, M*., Gundberg, A., Sivertsson, A., Schwenk, J, M., Uhlen, M., Nilsson, P (2011) Validation of various affinity reagents using protein microarrays. Manuscript submitted to New Biotechnology. All papers are reproduced with permission from the copyright holders *These authors contributed equally to this work. Related publications Colwill, K., Persson, H., Jarvik, N. E., Wyrzucki, A., Wojcik, J., Koide, A., Kossiakoff, A. A., Koide, S., Sidhu, S., Dyson, M. R., Pershad, K., Pavlovic, J. D., Karatt-Vellatt, A., Schofield, D. J., Kay, B. K., McCafferty, J., Mersmann, M., Meier, D., Mersmann, J., Helmsing, S., Hust, M., Dubel, S., Berkowicz, S., Freemantle, A., Spiegel, M., Sawyer, A., Layton, D., Nice, E., Dai, A., Rocks, O., Williton, K., Fellouse, F. A., Hersi, K., Pawson, T., Nilsson, P., Sundberg, M., Sjoberg, R., Sivertsson, A., Schwenk, J. M., Takanen, J. O., Hober, S., Uhlen, M., Dahlgren, L. G., Flores, A., Johansson, I., Weigelt, J., Crombet, L., Loppnau, P., Kozieradzki, I., Cossar, D., Arrowsmith, C. H., Edwards, A. M., and Graslund, S. (2011) A roadmap to generate renewable protein binders to the human proteome, Nat Methods 8, 551- 558. Rimini, R., Schwenk, J. M., Sundberg, M., Sjoberg, R., Klevebring, D., Gry, M., Uhlen, M., and Nilsson, P. (2009) Validation of serum protein profiles by a dual antibody array approach, J Proteomics 73, 252-266. Lundberg, E., Sundberg, M., Graslund, T., Uhlen, M., and Svahn, H. A. (2007) A novel method for reproducible fluorescent labeling of small amounts of antibodies on solid phase, J Immunol Methods 322, 40-49. Eriksson, C., Agaton, C., Kange, R., Sundberg, M., Nilsson, P., Ek, B., Uhlen, M., Gustafsson, M., and Hober, S. (2006) Microfluidic analysis of antibody specificity in a compact disk format, J Proteome Res 5, 1568-1574. Uhlen, M., Bjorling, E., Agaton, C., Szigyarto, C. A., Amini, B., Andersen, E., Andersson, A. C., Angelidou, P., Asplund, A., Asplund, C., Berglund, L., Bergstrom, K., Brumer, H., Cerjan, D., Ekstrom, M., Elobeid, A., Eriksson, C., Fagerberg, L., Falk, R., Fall, J., Forsberg, M., Bjorklund, M. G., Gumbel, K., Halimi, A., Hallin, I., Hamsten, C., Hansson, M., Hedhammar, M., Hercules, G., Kampf, C., Larsson, K., Lindskog, M., Lodewyckx, W., Lund, J., Lundeberg, J., Magnusson, K., Malm, E., Nilsson, P., Odling, J., Oksvold, P., Olsson, I., Oster, E., Ottosson, J., Paavilainen, L., Persson, A., Rimini, R., Rockberg, J., Runeson, M., Sivertsson, A., Skollermo, A., Steen, J., Stenvall, M., Sterky, F., Stromberg, S., Sundberg, M., Tegel, H., Tourle, S., Wahlund, E., Walden, A., Wan, J., Wernerus, H., Westberg, J., Wester, K., Wrethagen, U., Xu, L. L., Hober, S., and Ponten, F. (2005) A human protein atlas for normal and cancer tissues based on antibody proteomics, Mol Cell Proteomics 4, 1920-1932. Janzi, M., Odling, J., Pan-Hammarstrom, Q., Sundberg, M., Lundeberg, J., Uhlen, M., Hammarstrom, L., and Nilsson, P. (2005) Serum microarrays for large scale screening of protein levels, Mol Cell Proteomics 4, 1942-1947. Contents Introduction ................................................................................................................................. 1 Human Protein Atlas project ................................................................................................. 2 Affinity reagents used in protein microarrays ................................................................ 3 Antigens ..................................................................................................................................... 3 Antibodies ................................................................................................................................. 4 Polyclonal antibodies ........................................................................................................ 4 Monoclonal antibodies ...................................................................................................... 5 Antibody fragments .............................................................................................................. 6 Other kinds of affinity reagents ....................................................................................... 6 Protein microarrays - production and application ......................................................... 7 Different approaches of protein microarrays .............................................................. 7 Antigen microarray ............................................................................................................ 7 Antibody microarray ......................................................................................................... 8 Peptide microarray ............................................................................................................ 8 Reverse-phase microarrays ........................................................................................... 8 Production of protein microarrays ................................................................................... 9 Printing robots .................................................................................................................... 9 Surfaces and immobilization ....................................................................................... 10 Blocking of substrate ...................................................................................................... 11 Sample labeling and detection systems .................................................................. 12 Incubation, scanning and data evaluation ............................................................. 12
Load more

Recommended publications
  • HIV-1 Induces Cytoskeletal Alterations and Rac1 Activation During Monocyte-Blood-Brain Barrier Interactions
    Woollard et al. Retrovirology 2014, 11:20 http://www.retrovirology.com/content/11/1/20 RESEARCH Open Access HIV-1 induces cytoskeletal alterations and Rac1 activation during monocyte-blood–brain barrier interactions: modulatory role of CCR5 Shawna M Woollard1, Hong Li1, Sangya Singh1, Fang Yu2 and Georgette D Kanmogne1* Abstract Background: Most HIV strains that enter the brain are macrophage-tropic and use the CCR5 receptor to bind and infect target cells. Because the cytoskeleton is a network of protein filaments involved in cellular movement and migration, we investigated whether CCR5 and the cytoskeleton are involved in endothelial-mononuclear phagocytes interactions, adhesion, and HIV-1 infection. Results: Using a cytoskeleton phospho-antibody microarray, we showed that after co-culture with human brain microvascular endothelial cells (HBMEC), HIV-1 infected monocytes increased expression and activation of cytoskeleton- associated proteins, including Rac1/cdc42 and cortactin, compared to non-infected monocytes co-cultured with HBMEC. Analysis of brain tissues from HIV-1-infected patients validated these findings, and showed transcriptional upregulation of Rac1 and cortactin, as well as increased activation of Rac1 in brain tissues of HIV-1-infected humans, compared to seronegative individuals and subjects with HIV-1-encephalitis. Confocal imaging showed that brain cells expressing phosphorylated Rac1 were mostly macrophages and blood vessels. CCR5 antagonists TAK-799 and maraviroc prevented HIV-induced upregulation and phosphorylation of cytoskeleton-associated proteins, prevented HIV-1 infection of macrophages, and diminished viral-induced adhesion of monocytes to HBMEC. Ingenuity pathway analysis suggests that during monocyte-endothelial interactions, HIV-1 alters protein expression and phosphorylation associated with integrin signaling, cellular morphology and cell movement, cellular assembly and organization, and post-translational modifications in monocytes.
    [Show full text]
  • Protein Function Microarrays: Design, Use and Bioinformatic Analysis in Cancer Biomarker Discovery and Quantitation
    Chapter 3 Protein Function Microarrays: Design, Use and Bioinformatic Analysis in Cancer Biomarker Discovery and Quantitation Jessica Duarte , Jean-Michel Serufuri , Nicola Mulder , and Jonathan Blackburn Abstract Protein microarrays have many potential applications in the systematic, quantitative analysis of protein function, including in biomarker discovery applica- tions. In this chapter, we review available methodologies relevant to this fi eld and describe a simple approach to the design and fabrication of cancer-antigen arrays suitable for cancer biomarker discovery through serological analysis of cancer patients. We consider general issues that arise in antigen content generation, microar- ray fabrication and microarray-based assays and provide practical examples of experimental approaches that address these. We then focus on general issues that arise in raw data extraction, raw data preprocessing and analysis of the resultant preprocessed data to determine its biological signi fi cance, and we describe compu- tational approaches to address these that enable quantitative assessment of serologi- cal protein microarray data. We exemplify this overall approach by reference to the creation of a multiplexed cancer-antigen microarray that contains 100 unique, puri fi ed, immobilised antigens in a spatially de fi ned array, and we describe speci fi c methods for serological assay and data analysis on such microarrays, including test cases with data originated from a malignant melanoma cohort. Keywords Protein microarrays • Cancer–testis antigens • Cancer biomarker discovery • Bioinformatic analysis • Pipeline J. Duarte • J.-M. Serufuri • N. Mulder • J. Blackburn , D.Phil (*) Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences , University of Cape Town , N3.06 Wernher Beit North Building, Anzio Road, Observatory , Cape Town 7925 , South Africa e-mail: [email protected] X.
    [Show full text]
  • A Chip for the Detection of Antibodies in Autoimmune Diseases by Dr J
    A utoimmunity As published in CLI June 2005 A chip for the detection of antibodies in autoimmune diseases by Dr J. Schulte-Pelkum, Dr Ch.Hentschel, Dr J. Kreutzberger, Dr F. Hiepe & Dr. W. Schoessler Biochip technology has rapidly developed into a booming sec- tor in life sciences over the last few years. The several thousand articles dedicated to the topic of microarrays reflect the signifi- cance of the potential impact of this technology on the bio- sciences [1]. Most of the research has been carried out on gene expression analysis, where DNA microarrays make it possible to generate a vast amount of information from only a few experi- ments. Newly developed protein microarrays are designed for the detection, quantification and functional analysis of proteins (e.g., antibodies) [2]. Applications of protein microarrays include assessment of DNA-protein and protein-protein inter- actions. However, progress has been slow, in part because of the challenges posed by the natural differences between proteins and DNA molecules. Proteins are highly diverse conformational Table 1. Microarray results using sera from patients with rheumatic diseases. structures commonly consisting of twenty different amino acids, whereas DNA, apart from its sequence, has a relatively uniform structure. Proteins may be totally or partially hydrophilic, hydrophobic, acidic or basic. Furthermore, they may undergo post-translational modifications such as glycosylation, acetylation and/or phosphorylation. Up to now, only a relatively small number of scientists have used protein array technology to directly investigate autoimmune diseases. Protein microarrays are technically more sophisticated than DNA arrays due to the heterogeneity of protein molecules as well as the need to preserve the complex three-dimensional structure (conformational epitopes) and function of proteins after immobilisation on the chip surface [3].
    [Show full text]
  • Anti-CD Antibody Microarray for Human Leukocyte Morphology Examination Allows Analyzing Rare Cell Populations and Suggesting Preliminary Diagnosis in Leukemia
    www.nature.com/scientificreports OPEN Anti-CD antibody microarray for human leukocyte morphology examination allows analyzing rare Received: 11 March 2015 Accepted: 23 June 2015 cell populations and suggesting Published: 27 July 2015 preliminary diagnosis in leukemia Alina N. Khvastunova1,2,*, Sofya A. Kuznetsova1,2,3,*, Liubov S. Al-Radi3, Alexandra V. Vylegzhanina3, Anna O. Zakirova1,2, Olga S. Fedyanina2, Alexander V. Filatov4, Ivan A. Vorobjev5 & Fazly Ataullakhanov1,2,3 We describe a method for leukocyte sorting by a microarray of anti-cluster-of-differentiation (anti-CD) antibodies and for preparation of the bound cells for morphological or cytochemical examination. The procedure results in a “sorted” smear with cells positive for certain surface antigens localised in predefined areas. The morphology and cytochemistry of the microarray-captured normal and neoplastic peripheral blood mononuclear cells are identical to the same characteristics in a smear. The microarray permits to determine the proportions of cells positive for the CD antigens on the microarray panel with high correlation with flow cytometry. Using the anti-CD microarray we show that normal granular lymphocytes and lymphocytes with radial segmentation of the nuclei are positive for CD3, CD8, CD16 or CD56 but not for CD4 or CD19. We also show that the described technique permits to obtain a pure leukemic cell population or to separate two leukemic cell populations on different antibody spots and to study their morphology or cytochemistry directly on the microarray. In cases of leukemias/lymphomas when circulating neoplastic cells are morphologically distinct, preliminary diagnosis can be suggested from full analysis of cell morphology, cytochemistry and their binding pattern on the microarray.
    [Show full text]
  • Low-Density Protein Microarray on Nitrocellulose Membrane for the Detection of Human Cytokines
    C. Y. Yu, M. L. Liu, I. C. Kuan, et al Low-Density Protein Microarray on Nitrocellulose Membrane for the Detection of Human Cytokines Chi-Yang Yu, Mao-Lung Liu, I-Ching Kuan and Shiow-Ling Lee Department of Bioengineering, Tatung University, Taipei, Taiwan, Republic of China A low-cost, low-density protein microarray on nitrocellulose membrane was developed for the de- tection of human cytokines. The microarray was derived from chemiluminescent sandwich-type immunoassay. Anti-human IL-2 and anti-human IL-4 polyclonal antibodies were arrayed and im- mobilized on the membrane. After the membrane was blocked and then incubation with human cytokines IL-2 and IL-4, biotinylated anti-human IL-2 and anti-human IL-4 monoclonal antibodies were added to form complexes with the cytokines and the immobilized polyclonal antibodies. Streptavidin-horseradish peroxidase conjugate was applied to detect the level of biotin. Finally, substrates for peroxidase were added to initiate chemiluminescence. The printed spots were uni- form and consistent in size. Under optimized conditions, the limits of detection for human IL-2 and IL-4 were 0.5 and 0.125 ng/ml, respectively. The linear range of the calibration curves spanned over two orders of magnitude. The application of 10 ng/ml streptavidin-peroxidase polymer was found to facilitate the analysis process. Key words: Chemiluminescence, cytokine, microarray, nitrocellulose tions [5]. Human cytokines IL-2 and IL-4 were selected Introduction as model analytes to compare our system with others [6,7]. The microarray was based on chemiluminescent Protein microarray has become an important research sandwich-type immunoassay.
    [Show full text]
  • Original Article Potential Biomarkers of Idiopathic Pulmonary Fibrosis Discovered in Serum by Proteomic Array Analysis
    Int J Clin Exp Pathol 2016;9(9):8922-8932 www.ijcep.com /ISSN:1936-2625/IJCEP0036540 Original Article Potential biomarkers of idiopathic pulmonary fibrosis discovered in serum by proteomic array analysis Rui Niu1, Xiaohui Li2, Yuan Zhang3, Hui Wang1, Yongbin Wang1, Ying Zhang1, Wei Wang1 Departments of 1Respiratory Medicine, 2Nursing, 3Evidence-Based Medicine, Second Hospital of Shandong University, Shandong, China Received July 24, 2016; Accepted July 25, 2016; Epub September 1, 2016; Published September 15, 2016 Abstract: Idiopathic pulmonary fibrosis (IPF) is a serious interstitial pneumonia leading to considerable morbidity and mortality. The unavailability of prompt biomarkers for IPF has hampered our ability to uncover preventive and therapeutic measures for this disease in a well-timed manner. The objective of this study was to identify valuable IPF associated blood biomarkers for stratifying patients and predicting outcome. By analyzing the expression of proteins in sera of 50 IPF patients and 10 healthy individuals using Biotin Label-based Antibody Array, we identified a signature of 46 differentially expressed proteins including 15 up-regulated and 31 down-regulated proteins as potential IPF biomarkers. The PPI network showed strong and complex interactions between identified biomarkers while functional enrichment analysis revealed their implications in 589 biological processes and 40 KEGG meta- bolic pathways. Western blotting and RT-PCR validation results corroborated with the microarray data. Our research unearthed candidate biomarkers with great potential for diagnosis of IPF and suggested that recombinant throm- bopoietin and anti-CCL18 antibodies, as well as other identified biomarkers may represent a novel advance in the medical treatment of patients with IPF.
    [Show full text]
  • Capture Microarray for the Diagnosis of Systemic Lupus Erythematosus
    An Antibody-Based Leukocyte- Capture Microarray for the Diagnosis of Systemic Lupus Erythematosus The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Lin, Ming-Wei, Joshua W. K. Ho, Leonard C. Harrison, Cristobal G. dos Remedios, and Stephen Adelstein. 2013. An antibody-based leukocyte-capture microarray for the diagnosis of systemic lupus erythematosus. PLoS ONE 8(3): e58199. Published Version doi:10.1371/journal.pone.0058199 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10658106 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA An Antibody-Based Leukocyte-Capture Microarray for the Diagnosis of Systemic Lupus Erythematosus Ming-Wei Lin1,2.¤, Joshua W. K. Ho3., Leonard C. Harrison4, Cristobal G. dos Remedios5, Stephen Adelstein1,2* 1 Department of Clinical Immunology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia, 2 Discipline of Medicine, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia, 3 Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, 4 The Walter and Eliza Hall Institute of Medical Research, Department of Clinical Immunology and Burnet Clinical Research Unit, The Royal Melbourne Hospital, Parkville, Victoria, Australia, 5 Discipline of Anatomy, Bosch Institute, The University of Sydney, Sydney, New South Wales, Australia Abstract The diagnosis of Systemic Lupus Erythematosus (SLE) is challenging due to its heterogeneous clinical presentation and the lack of robust biomarkers to distinguish it from other autoimmune diseases.
    [Show full text]
  • Development of a Novel, Quantitative Protein Microarray Platform for the Multiplexed Serological Analysis of Autoantibodies to Cancer-Testis Antigens
    IJC International Journal of Cancer Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens Natasha Beeton-Kempen1,2*, Jessica Duarte1*, Aubrey Shoko3, Jean-Michel Serufuri1, Thomas John4,5, Jonathan Cebon4,5 and Jonathan Blackburn1 1 Institute of Infectious Disease and Molecular Medicine/Division of Medical Biochemistry, University of Cape Town, Cape Town, South Africa 2 Biosciences Division, Council for Scientific and Industrial Research, Pretoria, South Africa 3 Centre for Proteomic and Genomic Research, Cape Town, South Africa 4 Ludwig Institute for Cancer Research, Melbourne, Australia 5 Joint Ludwig-Austin Oncology Unit, Austin Health, Victoria, Australia The cancer-testis antigens are a group of unrelated proteins aberrantly expressed in various cancers in adult somatic tissues. This aberrant expression can trigger spontaneous immune responses, a phenomenon exploited for the development of disease markers and therapeutic vaccines. However, expression levels often vary amongst patients presenting the same cancer type, and these antigens are therefore unlikely to be individually viable as diagnostic or prognostic markers. Nevertheless, patterns of anti- gen expression may provide correlates of specific cancer types and disease progression. Herein, we describe the development of a novel, readily customizable cancer-testis antigen microarray platform together with robust bioinformatics tools, with which to quantify anti-cancer testis antigen autoantibody profiles in patient sera. By exploiting the high affinity between autoantibodies and tumor antigens, we achieved linearity of response and an autoantibody quantitation limit in the pg/mL range—equating to a million-fold serum dilution. By using oriented attachment of folded, recombinant antigens and a polyethylene glycol microarray surface coating, we attained minimal non-specific antibody binding.
    [Show full text]
  • PREPARATION of MICROARRAY for DISEASE DETECTION - a SURVEY on DIFFERENT METHODS Kavitha B1, Manjusha G Y2, Sachin D’Souza3 & Hemalatha N4
    International Journal of Latest Trends in Engineering and Technology Special Issue SACAIM 2017, pp. 088-090 e-ISSN:2278-621X PREPARATION OF MICROARRAY FOR DISEASE DETECTION - A SURVEY ON DIFFERENT METHODS Kavitha B1, Manjusha G Y2, Sachin D’Souza3 & Hemalatha N4 Abstract- Microarray is a pattern of ssDNA probes which are immobilized on a surface called a chip or a slide.It is used to detect the expression of thousands of gene at the same time. Microarrays (biochip) plays an important role in the drug discovery. The biochip is used to monitor changes in gene expression in response to drug treatments and also used to examine the response of the host against pathogen. The oligonucleotide microarrays provides a rapid, specific and high throughput means for the detection and identification of the food-borne pathogens. In this paper we have described microarray-based tests or methods for detecting the various kinds of diseases. By using several methods and tools like allergen microarray one can screen the serum IgE reactivity. cDNA microarrays has been developed for analysing estrogen responsive genes and in detecting anti hormone therapy. Evaluation of the potential of pathogenicity is determined by detection of a range of virulence factors and serotype determination. Micro RNA identifier array used for the detection of various type of micro RNA in human or for simultaneous detection and genotyping of different virus types in a single reaction. Keywords- Microarray, DNA, RNA,Gene 1. INTRODUCTION Microarray is multiplex lab on a chip. It is a pattern of ssDNA probes which are immobilized on a surface called chip or a slide.
    [Show full text]
  • Protein Microarray Technology: Assisting Personalized Medicine in Oncology (Review)
    WORLD ACADEMY OF SCIENCES JOURNAL 1: 113-124, 2019 Protein microarray technology: Assisting personalized medicine in oncology (Review) MONICA NEAGU1-3, MARINELA BOSTAN1,4 and CAROLINA CONSTANTIN1,2 1Department of Immunology, ‘Victor Babes’ National Institute of Pathology, 050096 Bucharest; 2Research Core of The Pathology Department, Colentina University Hospital, Bucharest 020125; 3Faculty of Biology, University of Bucharest, 050095 Bucharest; 4Immunology Center, ‘Stefan Nicolau’ Institute of Virology, 030304 Bucharest, Romania Received April 23, 2019; Accepted June 11, 2019 DOI: 10.3892/wasj.2019.15 Abstract. Among proteomics technologies, protein microarray, into the future. We present personalized medicine goals and over the past last years, has gained an increased momentum discuss how protein microarray can aid in these goals, with an in the biomarkers discovery domain. The characteristics of emphasis on several oncological diseases. We also discuss how protein microarray, namely that it is a high-throughput tool, it protein technology has been used in diseases, such as lung, provides a high specificity and only requires a minute amount breast cancers, as well as in other diseases that, over the past of biological samples, render it a suitable tool for searching, last years, have taken advantage of this proteomic endeavor. quantifying and validating biomarkers in various pathologies. Protein microarray is based on the specific antigen‑antibody reaction, such as any enzyme-linked immunosorbent assay, Contents the specific reaction occurring on a miniaturized support (chip or slide), thus having the advantage of simultaneous eval- 1. Introduction uation of tens to thousands of molecules in small samples with 2. Personalized medicine: A step forward in improving a highly specific recognition for the detection system.
    [Show full text]
  • Biomolecular Applications for Biomems Primary Knowledge Participant Guide
    Biomolecular Applications for bioMEMS Primary Knowledge Participant Guide Description and Estimated Time to Complete This learning module is an overview of biomolecules, what are they, types of biomolecules, and how microtechnology is using biomolecules or exploiting their functions for micro and nano-sized transducers, sensors and actuators. Activities provide the opportunity to better understand the function of biomolecules, their scale and why they are so important for micro and nanotechnologies. This unit discusses the characteristics and phenomena of biomolecules that make them attractive components for bioMEMS devices. It provides information that helps you understand how biological molecules can be used as working devices within bioMEMS. Estimated Time to Complete Allow at least 30 minutes to complete. Introduction A MEMS cantilever coated with a monolayer of biological molecules (probe surface layer) can bind with and capture other molecules (analytes) of complementary shapes Southwest Center for Microsystems Education (SCME) Page 1 of 26 App_BioMEM_PK36s_PG_August2017.docx Biomolecular Applications of bioMEMS PK As MEMS devices become smaller and smaller, the use of biomolecules as a MEMS component becomes more attractive. But how can biomolecules be used as a MEMS component? • Biomolecules can self-assemble into predictable and precise structures in the nano range. This offers a vast new repertoire of structures and functions to MEMS devices. • Many of these molecules’ functions in living organisms can be harnessed to perform the same functions in a bioMEMS device. This provides a wealth of materials and applications that can be applied to bioMEMS design. To understand how biomolecules can be used in bioMEMS, it is useful to learn about the types of biomolecules and how they associate with each other in functional units.
    [Show full text]
  • Lec-29-Handout
    NPTEL VIDEO COURSE – PROTEOMICS PROF. SANJEEVA SRIVASTAVA HANDOUT LECTURE-29 CELL-FREE SYNTHESIS BASED PROTEIN MICROARRAYS Slide 1: In today’s lecture we will talk about protein microarrays based on cell-free synthesis. So cell-free synthesis based protein microarrays provides a high throughput, versatile platform for large-scale analysis of functional proteins. These microarrays are used for various applications for eg, antibody profiling, biomarker discovery, enzyme-substrate identification, protein-protein interaction etc. The traditional cell based methods which were used for making the protein microarrays involve protein expression in heterologous system such as E. coli. But the protein purification is a very laborious process. It involves various steps and of the protein purity, protein integrity, its stability and the functionality. All of these remain major issues for protein purification. So if we have to generate high throughput, large number of proteins which is required for performing protein microarray studies, it is very tedious, because one need to purify large number of proteins in the scale of thousands and then maintain the functionality and keep them properly folded. So these limitations of traditional protein purification and protein microarrays generated by these purified proteins have been the major motivation for cell-free expression based microarray field. The cell-free expression based systems have overcome various limitations of protein purification and they perform in situ transcription and translation. Slide 2: I will give you an overview and the principle of various cell-free expression based protein microarrays. We will talk about protein in situ arrays (PISA), nucleic acid programmable protein arrays (NAPPA), multiple spotting technique (MIST), DNA array to protein array (DAPA) and HaloTag array.
    [Show full text]